Cyclooxygenase Inhibition Limits Blood-Brain Barrier Disruption following Intracerebral Injection of Tumor Necrosis Factor-α in the Rat
- 1 November 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 323 (2) , 488-498
- https://doi.org/10.1124/jpet.107.127035
Abstract
Increased permeability of the blood-brain barrier (BBB) is important in neurological disorders. Neuroinflammation is associated with increased BBB breakdown and brain injury. Tumor necrosis factor (TNF)-α is involved in BBB injury and edema formation through a mechanism involving matrix metalloproteinase (MMP) up-regulation. There is emerging evidence indicating that cyclooxygenase (COX) inhibition limits BBB disruption following ischemic stroke and bacterial meningitis, but the mechanisms involved are not known. We used intracerebral injection of TNF-α to study the effect of COX inhibition on TNF-α-induced BBB breakdown, MMP expression/activity, and oxidative stress. BBB disruption was evaluated by the uptake of 14C-sucrose into the brain and by magnetic resonance imaging utilizing gadolinium-diethylenetriaminepentaacetic acid as a paramagnetic contrast agent. Using selective inhibitors of each COX isoform, we found that COX-1 activity is more important than COX-2 in BBB opening. TNF-α induced a significant up-regulation of gelatinase B (MMP-9), stromelysin-1 (MMP-3), and COX-2. In addition, TNF-α significantly depleted glutathione as compared with saline. Indomethacin (10 mg/kg i.p.), an inhibitor of COX-1 and COX-2, reduced BBB damage at 24 h. Indomethacin significantly attenuated MMP-9 and MMP-3 expression and activation and prevented the loss of endogenous radical scavenging capacity following intracerebral injection of TNF-α. Our results show for the first time that BBB disruption during neuroinflammation can be significantly reduced by administration of COX inhibitors. Modulation of COX in brain injury by COX inhibitors or agents modulating prostaglandin E2 formation/signaling may be useful in clinical settings associated with BBB disruption.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Post‐ischaemic treatment with the cyclooxygenase‐2 inhibitor nimesulide reduces blood–brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in ratsJournal of Neurochemistry, 2006
- Blood–brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammationNeurobiology of Disease, 2006
- Association Between Prostaglandin E Receptor Subtype EP4 Overexpression and Unstable Phenotype in Atherosclerotic Plaques in HumanArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Signal transduction pathways regulating cyclooxygenase‐2 in lipopolysaccharide‐activated primary rat microgliaGlia, 2005
- Assessment of the relative contribution of COX‐1 and COX‐2 isoforms to ischemia‐induced oxidative damage and neurodegeneration following transient global cerebral ischemiaJournal of Neurochemistry, 2003
- Cell surface association of matrix metalloproteinase-9 (gelatinase B)Cancer and Metastasis Reviews, 2003
- S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell DeathScience, 2002
- Matrix Metalloproteinase Inhibition Prevents Oxidative Stress-Associated Blood–Brain Barrier Disruption after Transient Focal Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2001
- The influence of cytokines on the integrity of the blood-brain barrier in vitroJournal of Neuroimmunology, 1996
- The use of monochlorobimane to determine hepatic GSH levels and synthesisAnalytical Biochemistry, 1990